Erectile Dysfunction in Renal Failure and Transplant Patients

Julia V. Fiuk; Nicholas N. Tadros

Disclosures

Transl Androl Urol. 2019;8(2):155-163. 

In This Article

Definitions

CKD, a deterioration of kidney function due to multiple etiologies, is classified in stages based on patients' glomerular filtration rate (GFR), which measures the filtering capability of the kidneys. End stage renal disease (ESRD) is defined as CKD stage 6, requiring renal replacement therapy such as hemodialysis.

Pathophysiology of ED in CKD

It is important to note that the majority of studies in this area focus on patients either on dialysis or after receiving a renal transplant; limited data exists on pre-dialysis CKD patients with ED.[2]

Hormonal Abnormalities

Several hormonal abnormalities have been consistently noted in CKD patients. Total and free testosterone levels tend to be reduced, with a normal binding capacity and concentration of sex hormone binding globulin (SHBG). In acute renal failure these disturbances are reversible with return of renal function; in chronic renal failure, the hypogonadal changes seem to persist.[5] The cause of hypogonadism in this population is likely poor response of Leydig cells to stimulation, as serum luteinizing hormone (LH) levels are elevated in CKD patients and administration of HCG, with its LH-like actions, shows a minimal response in serum testosterone levels.[6] In vitro studies also suggest uremic serum may contain an LH receptor antagonist, which is inversely proportional to GFR and is virtually eliminated by renal transplant.[7] Follicle stimulating hormone (FSH) levels are also increased in men with CKD, thought to be secondary to decreased negative feedback from inhibin due to Sertoli cell damage from the uremic state.[7] Hyperprolactinemia, though rare in the general population, is common in men with CKD, likely due to increased production as the kidneys play little role in its catabolism and excretion.[8] This elevation in prolactin can lead to the suppression of the normal pulsatile release of gonadotropin-releasing hormone (GnRH).[9] Hyperprolactinemia can cause ED both via directly decreasing GnRH secretion, and thus ultimately testosterone, and by increasing the synthesis, turnover, and release of hypothalamic dopamine.[10,11] Secondary hyperparathyroidism and depletion of zinc reserves have been postulated as alternative causes of hyperprolactinemia in the CKD population.[12,13] These hormonal abnormalities in combination lead to the hypergonadotropic hypogonadal state of the CKD patient.

It is unclear whether uremic metabolites damage the Leydig and Sertoli cells of the testes more than they do hypothalamic and pituitary function, or if degradation of these metabolites occurs at a faster rate in the hypothalamus and pituitary than the testes. Both situations result in hypergonadotropic hypogonadism. Alternatively, as LH and prolactin are polypeptide hormones, their renal clearance may be decreased to a greater degree with impaired GFR than that of testosterone, which is a lipid-based hormone.[14] This would lead to increased LH and prolactin levels while simultaneously lowering testosterone levels, due to increased clearance, thus again resulting in hypergonadotropic hypogonadism.

The male hormonal milieu has been shown to play a critical role in ED. Low testosterone and high prolactin both lead to decreased libido. Several older studies have shown elevated prolactin levels are correlated with decreased libido.[15,16] It is important to note that hyperprolactinemia also leads to low testosterone through negative feedback in the hypothalamic—pituitary—gonadal axis, thus leading to potential confounding. Additionally, testosterone is critical for maintaining normal physiology of the penis, with low testosterone causing replacement of cavernosal smooth muscle with collagen fibers, potentially leading to corporal veno-occlusive dysfunction and fibrosis.[17] On the molecular level, nitrinergic activity, responsible for vasodilation, and PDE5 (phosphodiesterase-5), the enzyme responsible for cGMP degradation, are both influenced by testosterone.[18,19] The relationship between serum testosterone has been demonstrated in several studies. A 2006 cohort study of 434 men demonstrated that ED, although likely also due to a combination of factors such as metabolic syndrome, smoking, and depression, has serum testosterone less than 231 ng/dL as an independent risk factor.[20] An inverse relationship between probability of questionnaire self-reported symptoms and testosterone levels was demonstrated in an age stratified, random sampling of 3,200 men in the European Male Aging Study. Patients were more likely to report ED at the threshold T level of 245 ng/dL.[21]

Furthermore, there is evidence that testosterone therapy improves erectile function in men with testosterone deficiency. A 2016 prospective observational longitudinal study of 261 hypogonadal men on intramuscular testosterone therapy showed a 71% improvement in Index of Erectile Function (IIEF) scores within the first 3 months, with an additional 65% improvement by the end of the mean 4.25 years of treatment. The change in mean IIEF score over the duration of the study, baseline 7.8 to 21.96, indicated that many patients improved from being categorized as having severe ED to no ED.[22] Data from the recent double-blinded, placebo-controlled Testosterone Trials study supported this assertion, though to a lesser extent. In a randomized group of 790 hypogonadal men (baseline T less than 275 ng/dL) aged 65 or older receiving either testosterone gel or placebo for one year, the testosterone treated group saw a 2.64 points improvement in their IIEF erectile function domain, downstaging many patients from severe ED to moderate ED.[23] It is important to note that this study has received criticism for its industry funding, reliance on questionnaire responses, and lack of reporting of degree of serum testosterone level improvement. A 2017 meta-analysis of 14 randomized controlled studies, including 2,298 men, suggested that testosterone therapy improved the IIEF erectile function domain score by 2.31 when compared to placebo. The effects of therapy on erectile function were more pronounced in patients with a lower baseline testosterone (less than 231 vs. less than 345 ng/dL) and less effective in men with comorbidities such as diabetes mellitus or obesity.[24]

Cardiovascular and Endothelial Dysfunction

It is well established that CKD increases patients' risk for cardiovascular disease (CVD).[25] Endothelial dysfunction, which is noted early in CVD, is also a critical component of ED, as nitric oxide (NO) production is decreased in poorly functioning endothelial cells. Endothelial dysfunction, similar to that seen in CVD, has been reported in CKD—thus it is unsurprising that CKD patients also frequently report ED.[26] Furthermore, CKD patients often suffer from comorbid metabolic conditions, such as diabetes, hypertension, and dyslipidemia, each of which are risk factors for ED.[27–31] Thus CKD contributes to ED both indirectly, via associated metabolic conditions, and directly, via impact on endothelial function.

Nervous System Abnormalities

Autonomic neuropathy, which occurs both secondary to diabetes and independently in CKD patients, has been postulated as a potential cause for ED. One early study compared nocturnal penile tumescence rates and blood pressure responses to Valsalva maneuver, as a proxy for autonomic nervous system function, in both uremic and non-uremic patients. Uremic patients were found to have both lower nocturnal penile tumescence rates and abnormal Valsalva responses.[32] This suggests that uremia itself may lead to autonomic dysfunction and thus ED. Diabetes, in addition to potentially causing CKD, has been shown to cause peripheral neuropathy. Diabetic patients with decreased vibratory perception thresholds, a measure of peripheral nerve function, have been found to have higher rates of ED.[33]

Anemia and Erythropoietin Deficiency

Erythropoietin (EPO) is a cytokine secreted by the interstitial cells in the peritubular capillary bed of the kidney cortex in response to hypoxia and is responsible primarily for upregulating red blood cell production in the bone marrow. CKD patients do not have an appropriate increase in EPO secretion in times of hypoxia, and thus often experience a chronic anemic state. EPO is commonly used to treat anemia in CKD patients; and several studies report that use of EPO in CKD patients on dialysis improved erectile function.[34–36] The mechanism by which EPO administration improves ED is not entirely clear, though several theories have been postulated. EPO has been shown to normalize elevated prolactin levels in early studies, though later studies did not confirm this finding.[37–40] EPO was also shown to increase serum testosterone in some studies, but was inconclusive in others.[34,35,38–41] An early study using 4 weeks of recombinant EPO therapy demonstrated a decrease in serum prolactin from 39.5±10.5 to 10.3±1.0 ng/mL in male dialysis patients, while serum testosterone levels remained unchanged.[34] Another small cohort of dialysis patients on EPO demonstrated a mild increase in anterior pituitary function, and thus downstream circulating testosterone, after receiving EPO treatment.[38] It is possible that EPO has a more direct impact on erectile function, as demonstrated by increased regeneration of the injured cavernous nerve after EPO administration in a rat model.[42] EPO has also been shown to have anti-apoptotic effects, thus protecting the cavernous nerve against ischemic injury.[43,44] The natural receptor for EPO is expressed on vascular endothelial cells; when EPO binds to this receptor, it stimulates their proliferation and migration. Additionally, EPO binding mobilizes endothelial progenitor cells from the bone marrow, which differentiate into vascular endothelial cells. These progenitor cells have been shown to migrate to the capillaries and small arteries of ischemic tissues in vivo, thus stimulating angiogenesis.[45] It has been reported that ED patients have low numbers of circulating endothelial progenitor cells; thus treatment with EPO may restore this imbalance and improve erectile function via increased angiogenesis.[46–48] It appears that EPO plays a multifactorial role in improving erectile function in CKD patients through its neuroprotective, anti-apoptotic and angiogenic properties.

Vitamin D Deficiency and Secondary Hyperparathyroidism

Vitamin D, in its inactive precursor form, is obtained either via diet or through skin synthesis. It then undergoes two hydroxylation steps to become active, first in the liver and then primarily the kidney, with additional secondary hydroxylation sites having been described recently.[49–51] With a decrease in the second hydroxylation step, CKD patients typically have severe hypovitaminosis D. Although there is a lack of conclusive evidence, it has been reported that treatment with 1,25 (OH) D3 decreased serum PTH concentrations and improved erectile function in patients on dialysis.[52] PTH administration has also been shown to increase serum prolactin levels, thereby potentially implicating secondary hyperparathyroidism as an etiologic factor for ED in CKD patients.[12]

Zinc Deficiency

Zinc deficiency has recently been demonstrated in a subset of CKD patients, and may explain EPO resistant anemia in this population.[53] CKD patients, particularly those on hemodialysis, suffer from zinc depletion via direct removal during hemodialysis and decreased GI absorption, and demonstrate an increased reticulocyte count and improved erythropoietin response after correcting low serum zinc levels. The mechanism behind this is not entirely clear but may be related to zinc-finger regions of transcription proteins regulating hematopoietic progenitor cell development.[53,54] Oral zinc supplementation in this population has also been shown to increase serum testosterone levels and improve erectile function.[55,56] However, at least one independent study showed no reversal of ED with zinc supplementation in this population.[57]

Psychosocial Factors

There is increasing evidence that psychosocial factors, such as depression, anxiety, and health-related quality of life impact the pathophysiology of chronic disease. In CKD, depression in particular has been studied in depth, with dialysis patients having an increased risk of depressed and consequent risk of mortality as well as poor health-related quality of life.[58] Up to 30% of CKD patients meet the criteria for clinical depression.[59–61] Depression has been shown to be an independent risk factor for ED in several studies, thus increasing the ED risk in the CKD population.[62,63]

Medication Effects

CKD patients are often prescribed multiple medications, many of which are known to contribute to ED. Antihypertensive drugs, particularly thiazide diuretics, aldosterone receptor blockers, and beta-adrenergic receptor blockers have been implicated in ED in CKD patients.[64] Additionally, cimetidine, tricyclic antidepressants, and metoclopramide may exacerbate ED symptoms in these patients.[65–68]

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....